Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

They could also offer a more potent option to conventional flu shots, according to mRNA vaccine developers. Current flu vaccines generally offer only around 40% to 60% protective efficacy ...

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Kennedy Jr. has alluded to in the past, this could have major repercussions for vaccine developers. Companies like Moderna (NASDAQ:MRNA) spend years playing by the rules of the FDA. If authorities ...

Related: Scientists behind tech in mRNA vaccines snag 2nd prestigious prize — is a Nobel next? Holst and his colleagues ...

uses a powerful monitoring system to reveal how the human immune system is responsive to a litany of tick triggers — some of which might be leveraged to create a protective mRNA vaccine.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s Squawk on the Street ...

Scientists at Shinshu University School of Medicine have developed a synthetic mRNA that, when injected, revitalizes the immune system to recognize and attack metastasizing cancer cells.

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

Federal support for mRNA vaccine research appears in jeopardy after KFF Health News reported Sunday that officials at the National Institutes of Health have directed scientists to remove all ...

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against ...

They found that mRNA-based COVID-19-vaccinations cause a significant and persistent change through acetylation, i.e., the binding of a chemical group to specific, immunologically relevant genes of ...